Wednesday, July 13, 2011

Slumdog Clinical Trials contd. - Fault Lines - Outsourced: Clinical trials overseas


US Pharmaceutical companies have moved their operations overseas over the course of the past decade. Instead of testing trial medicines on Americans, more and more of these tests are being carried out on poor people in faraway places. Russia, China, Brazil, Poland, Uganda, and Romania are all hot spots for what is called clinical research or clinical trials. Now employing CROs—or Clinical Research Organizations—the industry is big business, worth as much as $30 billion US dollars today.

One country has experienced a boom like no other in this industry--India. Spoken English, an established medical infrastructure, welcome attitudes toward foreign industry and most importantly legions of poor, illiterate test subjects that are willing to try out new drugs have transformed the Indian landscape into a massive testing ground for pharmaceuticals. Fault Lines' Zeina Awad travels to India to see what the clinical research practices look like on the ground. What role are the US regulatory bodies playing in overseeing the trials? Are participants aware that they are taking part in a clinical trial? Is the testing being held up against international ethical standards?

http://english.aljazeera.net/programmes/faultlines/

Follow us on Twitter: http://twitter.com/AJFaultLines
Follow us on Facebook: http://facebook.com/AJFaultLines
Follow us on Tumblr: http://ajfaultlines.tumblr.com

See all episodes of Fault Lines: http://www.youtube.com/show/faultlines?s=2010

Meet the Fault Lines staff: http://www.youtube.com/playlist?p=PL2A3A165068A8A650


With over a billion residents, India is one of the growing destinations for the multi-million industry, Wired reports. Clinical research organizations cite the country's enormous population as the main reason for its appeal for clinical tests, but al Jazeera's current affairs show Fault Lines wonders if India's growing gap between rich and poor doesn't complicate that P.R. picture.


Hat tip: HuffPo

No comments: